Ponatinib, bosutinib, and repotrectinib are FDA-approved for the treatment of acute lymphoblastic leukemia, childhood chronic myeloid leukemia, and ROS1-positive non-small cell lung cancer, respectively. Here, ROS1 is linked to non-small cell lung carcinoma.